## **Andrew Smirnov**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3373282/publications.pdf

Version: 2024-02-01

933264 752573 40 471 10 20 citations h-index g-index papers 41 41 41 657 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prevalences and correlates of non-viral injecting-related injuries and diseases in a convenience sample of Australian injecting drug users. Drug and Alcohol Dependence, 2009, 100, 9-16.	1.6	78
2	Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network. International Journal of Drug Policy, 2017, 47, 216-220.	1.6	78
3	Prevalence and predictors of injectingâ€related injury and disease among clients of Australia's needle and syringe programs. Australian and New Zealand Journal of Public Health, 2008, 32, 34-37.	0.8	46
4	Clinical effectiveness, cost effectiveness and acceptability of communityâ€based treatment of hepatitis C virus infection: AÂmixed method systematic review. Journal of Viral Hepatitis, 2019, 26, 432-453.	1.0	21
5	Young adults' trajectories of Ecstasy use: A population based study. Addictive Behaviors, 2013, 38, 2667-2674.	1.7	20
6	Simultaneous use of alcohol with methamphetamine but not ecstasy linked with aggression among young adult stimulant users. Addictive Behaviors, 2017, 70, 27-34.	1.7	20
7	Prevention of Alcoholâ€Exposed Pregnancies and Fetal Alcohol Spectrum Disorder Among Pregnant and Postpartum Women: A Systematic Review. Alcoholism: Clinical and Experimental Research, 2020, 44, 2431-2448.	1.4	20
8	Young adults' recreational social environment as a predictor of ecstasy use initiation: findings of a populationâ€based prospective study. Addiction, 2013, 108, 1809-1817.	1.7	19
9	Intimate partner violence in emerging adulthood and subsequent substance use disorders: findings from a longitudinal study. Addiction, 2019, 114, 1264-1273.	1.7	19
10	Enablers and barriers for the provision of communityâ€based HCV treatment: A case study of a realâ€world practice. Journal of Viral Hepatitis, 2020, 27, 484-496.	1.0	16
11	Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general practice settings in Australia. Journal of Substance Abuse Treatment, 2021, 127, 108460.	1.5	14
12	Using population screening for recruitment of young adults engaged in illicit drug use: Methodological issues and sampling outcomes. Social Science Research, 2014, 45, 89-97.	1.1	12
13	Hepatitis C cascade of care at an integrated community facility for people who inject drugs. Journal of Substance Abuse Treatment, 2020, 114, 108025.	1.5	12
14	The economic burden to the public health system of treating nonâ€viral injectingâ€related injury and disease in Australia (a cost of illness analysis). Australian and New Zealand Journal of Public Health, 2009, 33, 352-357.	0.8	10
15	Elements of communityâ€based models for treating hepatitis C virus in supporting HCV elimination in Australia: A Delphi study. International Journal of Health Planning and Management, 2019, 34, e1247-e1256.	0.7	9
16	â€~l'm over the moon!': patient-perceived outcomes of hepatitis C treatment. Australian Journal of Primary Health, 2020, 26, 319.	0.4	9
17	Willingness to cooperate with police: A population-based study of Australian young adult illicit stimulant users. Criminology and Criminal Justice, 2017, 17, 301-318.	1.0	7
18	Prescribing directâ€acting antivirals to treat hepatitis C virus in a general practice setting in Australia: †so why not do it'?. Internal Medicine Journal, 2020, 50, 1053-1058.	0.5	6

#	Article	IF	CITATIONS
19	Australian National Minimum Data Set for Clients of Alcohol and Other Drug Treatment Services: findings of the national pilot and developments in implementation. Drug and Alcohol Review, 2001, 20, 295-298.	1.1	5
20	Use and Misuse of Opioid Replacement Therapies: A Queensland Study. Substance Use and Misuse, 2012, 47, 78-85.	0.7	5
21	Outcomes of a tertiary-based innovative approach to engage primary care providers in provision of hepatitis C treatment in community settings. BMC Public Health, 2019, 19, 1335.	1.2	5
22	Neurodevelopmental disorders in youth justice: a systematic review of screening, assessment and interventions. Journal of Experimental Criminology, 2023, 19, 31-70.	1.9	5
23	Patterns of drug dependence in a Queensland (Australia) sample of Indigenous and nonâ€Indigenous people who inject drugs. Drug and Alcohol Review, 2016, 35, 611-619.	1.1	4
24	When Knowledge and Experience Do Not Help: A Study of Nonfatal Drug Overdoses. Journal of Addiction Medicine, 2017, 11, 280-285.	1.4	4
25	Predictors of Aggressive Behavior While under the Influence of Illicit Drugs among Young Adult Methamphetamine Users. Substance Use and Misuse, 2018, 53, 2439-2443.	0.7	4
26	Framework for community-based models for treating hepatitis C virus. Australian Health Review, 2020, 44, 459.	0.5	4
27	Social Contacts and Ecstasy Offers: Findings of a Population-Based Study. Journal of Psychoactive Drugs, 2013, 45, 425-433.	1.0	3
28	Experiences of police contact among young adult recreational drug users: A qualitative study. International Journal of Drug Policy, 2018, 56, 64-72.	1.6	3
29	The prevalence of mental health disorders among young adults who use amphetamineâ€type stimulants, compared to young adults who do not. Drug and Alcohol Review, 2021, 40, 557-566.	1.1	3
30	Engagement with different nightlife venues and frequent ecstasy use in a young adult population. Drugs: Education, Prevention and Policy, 2015, 22, 380-384.	0.8	2
31	Hepatitis C viral infection and imprisonment among Aboriginal and Torres Strait Islander and nonâ€Indigenous people who inject drugs. Drug and Alcohol Review, 2018, 37, 831-836.	1.1	2
32	Reasons for Not Seeking Hepatitis C Treatment among People Who Inject Drugs. Substance Use and Misuse, 2021, 56, 175-184.	0.7	2
33	How can general practitioners support people who inject drugs to engage with direct-acting antiviral treatment for hepatitis C? A qualitative study. Australian Journal of General Practice, 2021, 50, 716-721.	0.3	2
34	Barriers and enablers to hepatitis C treatment among clients of Aboriginal Community Controlled Health Services in South East Queensland, Australia: a qualitative enquiry. Australian Journal of Primary Health, 2022, 28, 239-246.	0.4	2
35	Psychological Distress and Drug Use Patterns of Young Adult Ecstasy Users: A Complementary Analysis of Australian Datasets. Substance Use and Misuse, 2014, 49, 77-86.	0.7	0
36	Predictors of Hazardous Alcohol Consumption Among Young Adult Amphetamine-Type Stimulant Users. SAGE Open, 2016, 6, 215824401662952.	0.8	0

3

#	Article	IF	CITATIONS
37	Co–administering cannabis with tobacco and persistent tobacco smoking after 4½ years in young adults who use stimulants: A prospective population–based study. Journal of Psychoactive Drugs, 2021, , 1-10.	1.0	0
38	The Relationship between Cannabis and Tobacco Co-administration and Long-Term Patterns of Cannabis Use in Young Adults Who Use Stimulants: A Prospective Population-Based Study. Substance Use and Misuse, 2022, 57, 11-20.	0.7	0
39	Injecting drug use opportunities and reasons for choosing not to inject: A populationâ€based study of Australian young adults who use stimulants. Drug and Alcohol Review, 2022, , .	1.1	0
40	Examining incarceration rates of Aboriginal and Torres Strait Islander children. The Lancet Child and Adolescent Health, 2022, 6, 599-600.	2.7	0